NEW YORK, Jan 7, 2026, 21:13 EST — Market closed
Danaher Corporation (DHR.N) stock slipped on Wednesday, closing at $235.60, down 0.42%. The shares were last up 0.16% in extended trading.
The life-sciences and diagnostics group is heading into a crowded calendar. Danaher said Chief Executive Rainer M. Blair will present at the J.P. Morgan Healthcare Conference in San Francisco on Jan. 13, and it has set its fourth-quarter earnings call for Jan. 28.
Evercore ISI analyst Vijay Kumar raised his 12-month price target — an estimate of where a stock could trade — to $250 from $245 and kept an Outperform rating. He said recovering end markets and “sector rotation” have “set the stage for a 2026 Tools play,” a nod to investors rotating back into makers of lab instruments and consumables.
TD Cowen lifted its target to $270 from $260 and reiterated a Buy rating on Danaher, TheFly reported. The firm said the bar is higher for the fourth-quarter print after a recent rally, but noted many companies have already “soft guided” 2026 — essentially setting cautious early expectations — which can leave room for upside.
U.S. stocks ended mixed: the S&P 500 fell 0.3% and the Dow dropped 0.9%, while the Nasdaq edged higher. Traders also assessed fresh labor readings and looked to Friday’s U.S. payrolls report.
Peers were mixed, with Thermo Fisher Scientific down 0.6% and Agilent Technologies up 0.1%. Danaher traded between $233.26 and $238.00 on the day, with about 2.7 million shares changing hands, and its 52-week range runs from $171.00 to $268.32.
On the charts, traders are watching support near $233 and resistance around $238, levels flagged by Barchart’s pivot points. A break either way can draw fast money into Thursday’s session.
But the setup cuts both ways. If management’s tone on orders and 2026 demand turns more cautious, or if the conference slot adds little new, the stock may struggle to hold a bid into earnings.
Next is Blair’s presentation at the J.P. Morgan Healthcare Conference on Jan. 13, followed by Danaher’s fourth-quarter call on Jan. 28. Investors will be listening for any change in 2026 expectations and for detail on demand across life sciences and diagnostics.
